1:25 PM
Mar 12, 2018
 |  BC Extra  |  Company News

Gilead names new CSO, CMO as Bischofberger departs

Gilead Sciences Inc. (NASDAQ:GILD) said Norbert Bischofberger will step down as EVP of R&D and CSO at the end of April. EVP of Clinical Research John McHutchison will become CSO and lead Gilead's R&D organization.

The company also named EVP of Clinical R&D Andrew Cheng as its next CMO, effective next month.

At Gilead, McHutchison and Cheng have led development of therapies for HCV and HIV, respectively. The biotech has been successful at crafting first-in-class and best-in-class combinations in both disease areas. Gilead has said it aims to apply a similar approach to innovation in its cancer business, particularly as it relates to the CAR T cell business it gained in its 2017 acquisition of Kite Pharma Inc. (see BioCentury, Sept. 8, 2017).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD